In order to meet the needs of epidemic prevention and control, promote the fair and reasonable detection of New Coronavirus antigen detection, reasonably control the price level and reduce the social and economic burden, today, the office of the national health insurance agency issued the notice on strengthening the price management of New Coronavirus antigen detection (hereinafter referred to as the notice). According to the circular, the provincial health insurance departments should make clear the policy before April 8, 2022, and allow for the detection of New Coronavirus antigen (hereinafter referred to as "new crown antigen") in public medical institutions, allowing the fees to be charged according to the "price item + testing reagent". Among them, the price of "new coronavirus antigen detection" is set by the provincial medical security department according to the government guidance price (ceiling price) of no more than 5 yuan per person per time; Neocoronavirus antigen detection reagents (including sampling instruments) shall be sold at a zero difference rate according to the actual purchase price. For the total charge of "price items + detection reagents" for the detection of neocoronavirus antigen, each provincial medical security department shall set a capping standard. At this stage, the capping standard shall not be higher than 15 yuan per person per time. If qualified, the capping standard can be reduced to a more reasonable level. Public medical institutions should be required to waive outpatient examination fees for people who simply detect neocoronavirus antigen; In the process of seeing a doctor, if the public medical institution provides the test reagent and the patient tests the neocoronavirus antigen, the public medical institution shall not charge the price item of "neocoronavirus antigen test". Referring to the existing online purchase prices in the country, the provincial medical security departments will further reduce the purchase costs of public medical institutions by organizing and implementing bidding online and participating in inter provincial alliance procurement before April 30. Public medical institutions shall purchase the required neocoronavirus antigen detection reagents on the centralized pharmaceutical procurement platform of the province (autonomous region and municipality directly under the central government), and shall not purchase offline. It is reported that before the "New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth)" requires additional antigen detection as a supplement to further improve the ability of early detection of cases. Immediately, the office of the National Medical Insurance Bureau issued a notice requiring antigen detection and neocrown treatment drugs to be temporarily included in the medical insurance of each province. (outlook new era)